EMBO Member
EMBO 2020
Our lab studies mechanisms of gut-brain communication enabling development of novel classes of drug candidates to prevent or reverse diabetes, obesity and metabolic diseases. These gut hormone polyagonist drugs are hybrid molecules of different peptide sequences that in some cases are coupled to small molecules. They show anti-obesity and anti-diabetic effects in animals and show promise in early clinical studies, due to their superior efficacy.
Keywords: Ghrelin / obesity / diabetes / metabolic disease / peptides / polyagonists
Subject area(s): Cellular Metabolism | Molecular Medicine | Signal Transduction